Welcome to our dedicated page for ZyVersa Therapeutics SEC filings (Ticker: ZVSA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The ZyVersa Therapeutics, Inc. (ZVSA) SEC filings page on Stock Titan brings together the company’s regulatory disclosures, offering a structured view of how this clinical-stage biopharmaceutical company reports its activities to the U.S. Securities and Exchange Commission. ZyVersa focuses on developing first-in-class drugs for renal and inflammatory diseases, and its filings provide detailed information on financial performance, capital structure, risk factors, and pipeline progress for Cholesterol Efflux Mediator™ VAR 200 and Inflammasome ASC Inhibitor IC 100.
Key documents for ZyVersa include quarterly reports on Form 10-Q and any related Form 12b-25 (NT 10-Q) notifications, which explain delays in filing and highlight significant changes in results, such as non-cash impairment charges related to in-process research and development. These filings give insight into research and development spending, general and administrative expenses, net losses, and the company’s assessment of its liquidity and need for additional financing.
Investors can also review multiple current reports on Form 8-K that ZyVersa files to disclose material events. Recent 8-Ks describe equity purchase agreements with institutional investors, warrant exercise inducement transactions, delisting notices from The Nasdaq Stock Market, changes in executive and board positions, and the announcement of financial results. One 8-K, together with a Form 25, documents the removal of ZyVersa’s common stock from listing on Nasdaq and notes that the stock is quoted on the OTCQB Venture Market under the symbol ZVSA.
For those tracking capital markets activity, ZyVersa’s registration statement on Form S-1 outlines an offering and resale framework associated with its equity purchase agreement, including the number of shares that may be issued and the registration rights granted to the investor. The Form 25 (25-NSE) filing confirms the delisting of the company’s common stock from Nasdaq under Exchange Act Rule 12d2-2.
On Stock Titan, these filings are supplemented with AI-powered summaries that explain the core points of each document in accessible language. Users can quickly see what ZyVersa reports about its financial condition, financing arrangements, listing status, and development programs, then drill down into the full 10-Q, 8-K, S-1, NT 10-Q, or Form 25 text as needed. The page also provides convenient access to insider and governance-related disclosures that appear in 8-K items about director and officer departures or appointments.
ZyVersa Therapeutics, Inc. reported that independent director Robert G. Finizio has resigned from the company’s Board of Directors, effective immediately. He also stepped down as Chairman of the Compensation Committee and as a member of the Audit Committee. The company states that his resignation is due to personal reasons and is not the result of any disagreement regarding ZyVersa’s operations, policies, or practices. ZyVersa’s common stock, par value $0.0001 per share, is quoted on the OTCQB Venture Market under the symbol ZVSA.
ZyVersa Therapeutics, Inc. (ZVSA) filed a current report to announce that it released a press release with its unaudited financial results for the quarter ended September 30, 2025. The press release is included as Exhibit 99.1 and is being furnished rather than filed, which means it is not automatically subject to certain liability provisions under the securities laws or incorporated into other securities filings unless specifically referenced. The company’s common stock, par value $0.0001 per share, trades under the symbol ZVSA and is quoted on the OTCQB Venture Market.
ZyVersa Therapeutics, Inc. reported a sharply higher Q3 2025 loss driven by a major write-down of R&D assets and continued cash burn. Net loss for the quarter was $19.8 million versus $2.4 million a year earlier, and $24.3 million for the nine months versus $8.0 million, largely due to an $18.6 million impairment of in-process research and development after a sustained decline in market capitalization.
Operating expenses rose to $20.8 million in Q3 2025 from $2.3 million, while research and development and general and administrative costs both declined year over year. Cash was $0.5 million at September 30, 2025, with a working capital deficit of $11.8 million and an accumulated deficit of $136.9 million. The company used $4.7 million of cash in operations over nine months and raised $3.7 million via a March 2025 private warrant placement and a July 2025 warrant inducement.
Management states that these conditions raise substantial doubt about ZyVersa’s ability to continue as a going concern. In July 2025, Nasdaq denied continued listing, and the common stock was delisted on October 6, 2025; trading moved to the OTCQB under the symbol ZVSA.
ZyVersa Therapeutics filed a Form 12b-25, indicating it cannot submit its Quarterly Report on Form 10‑Q for the quarter ended September 30, 2025 without unreasonable effort or expense. The company expects to file within the five‑day extension period permitted under Rule 12b‑25.
The company stated it is completing management’s review of its quarter‑end consolidated financial statements and related disclosures. It also disclosed that the results to be included in the Form 10‑Q will reflect significant changes in net loss from the prior‑year period due to an $18.6 million non‑cash impairment charge related to in‑process research and development. Forward‑looking statements caution that actual timing and outcomes may differ.
ZyVersa Therapeutics announced a leadership change. On October 10, 2025, Pablo Guzman, M.D., resigned as Chief Medical Officer and Senior Vice President of Medical Affairs. Dr. Guzman joined the company in January 2015 after more than 35 years practicing interventional cardiology in South Florida and serving as a managing partner of Cardiology Associates of Fort Lauderdale. The company states he resigned to spend more time with his family and to travel.
ZyVersa Therapeutics, Inc. (ZVSA) submitted a Form 25 notice indicating removal of its securities from listing and/or registration on the Nasdaq Stock Market LLC. The filing identifies the issuer's principal office in Weston, Florida, and provides a contact telephone number. The form lists the regulatory provisions for voluntary or exchange-initiated delisting under 17 CFR 240.12d2-2 and certifies Nasdaq's compliance with the rule for striking the class from listing and/or registration.
ZyVersa Therapeutics, Inc. reports that the Nasdaq Stock Market plans to delist its common stock following the filing of a Form 25 with the SEC on or about September 18, 2025. The delisting will become effective ten days after the Form 25 is filed under Exchange Act Rule 12d2-2.
The company’s common stock was suspended from trading on The Nasdaq Capital Market on July 17, 2025 after failing to regain compliance with Nasdaq’s minimum bid price requirement, and it has been trading on the OTCQB Venture Market under the symbol “ZVSA” since July 28, 2025. ZyVersa states that its common stock will continue trading on the OTCQB without disruption.
FAQ
What is the current stock price of ZyVersa Therapeutics (ZVSA)?
What is the market cap of ZyVersa Therapeutics (ZVSA)?
